Ocugen Partners with Global Alliance for Regenerative Medicine for Patient Care
1 report, 1 independent
Updated Wed 00:00
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Ocugen executed an agreement with Global Alliance for Regenerative Medicine to coordinate and manage patient care. The company also received Provisional Approval and Priority Designation for OCU400 in The Bahamas. As of September 30, 2026, Ocugen reported holding $84.6 million in cash and cash equivalents, with an expected runway into 2028.
From manilatimes.net
Why it matters
The partnership allows Ocugen to expand its global reach and advance its pipeline by leveraging strategic partnerships. Ocugen is also advancing its commercial opportunities, including an exclusive OCU400 license agreement for the Middle East and North Africa with Roots Pharmaceutical.
From manilatimes.net
Who's involved
- OcugenExecuted the agreement with Global Alliance for Regenerative Medicine to manage patient care.
- Global Alliance for Regenerative MedicineEntered into an agreement with Ocugen to coordinate and manage patient care.
Keep exploring
The entities involved
-
Ocugen
biopharmaceutical company
Nothing else this week.